Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study

Abstract Danish nationwide registries were used to investigate temporal trends in initiation of rivaroxaban or apixaban or dabigatran versus vitamin K antagonists (VKA) in patients with venous thromboembolism (VTE). Patients treated with one of the NOACs (rivaroxaban, dabigatran, apixaban) or VKA we...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Caroline Sindet-Pedersen, Jannik Langtved Pallisgaard, Laila Staerk, Jeffrey S. Berger, Morten Lamberts, Christian Torp-Pedersen, Gunnar H. Gislason, Jonas Bjerring Olesen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a356c7fa19f545c8a9a069f90130ab95
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a356c7fa19f545c8a9a069f90130ab95
record_format	dspace
spelling	oai:doaj.org-article:a356c7fa19f545c8a9a069f90130ab952021-12-02T15:05:43ZTemporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study10.1038/s41598-017-03596-x2045-2322https://doaj.org/article/a356c7fa19f545c8a9a069f90130ab952017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-03596-xhttps://doaj.org/toc/2045-2322Abstract Danish nationwide registries were used to investigate temporal trends in initiation of rivaroxaban or apixaban or dabigatran versus vitamin K antagonists (VKA) in patients with venous thromboembolism (VTE). Patients treated with one of the NOACs (rivaroxaban, dabigatran, apixaban) or VKA were identified between February 2012 and September 2016. A total of 19,578 patients were included of which 10,844 (55.4%) were treated with VKA and 8,734 (44.6%) were treated with NOACs (rivaroxaban 7,572, apixaban 1,066, and dabigatran 96). Temporal trends showed a decrease in the initiation of VKA (p-value for decreasing trend, p < 0001) and an increase in the initiation of rivaroxaban and apixaban (p-value for increasing trend, p < 0001). By September 2016, 12%, 70%, 16%, and 2% of patients with VTE were initiated on VKA, rivaroxaban, apixaban, and dabigatran. Patients with previous VTE, chronic kidney disease, liver disease, cancer, and thrombophilia were more likely to be initiated on VKA compared with one of the NOACs. In conclusion the initiation of rivaroxaban and apixaban is increasing significantly over time in patients with VTE. Patients with previous VTE, chronic kidney disease, liver disease, cancer, and thrombophilia were more likely to be initiated on VKA compared with rivaroxaban or apixaban.Caroline Sindet-PedersenJannik Langtved PallisgaardLaila StaerkJeffrey S. BergerMorten LambertsChristian Torp-PedersenGunnar H. GislasonJonas Bjerring OlesenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Caroline Sindet-Pedersen Jannik Langtved Pallisgaard Laila Staerk Jeffrey S. Berger Morten Lamberts Christian Torp-Pedersen Gunnar H. Gislason Jonas Bjerring Olesen Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
description	Abstract Danish nationwide registries were used to investigate temporal trends in initiation of rivaroxaban or apixaban or dabigatran versus vitamin K antagonists (VKA) in patients with venous thromboembolism (VTE). Patients treated with one of the NOACs (rivaroxaban, dabigatran, apixaban) or VKA were identified between February 2012 and September 2016. A total of 19,578 patients were included of which 10,844 (55.4%) were treated with VKA and 8,734 (44.6%) were treated with NOACs (rivaroxaban 7,572, apixaban 1,066, and dabigatran 96). Temporal trends showed a decrease in the initiation of VKA (p-value for decreasing trend, p < 0001) and an increase in the initiation of rivaroxaban and apixaban (p-value for increasing trend, p < 0001). By September 2016, 12%, 70%, 16%, and 2% of patients with VTE were initiated on VKA, rivaroxaban, apixaban, and dabigatran. Patients with previous VTE, chronic kidney disease, liver disease, cancer, and thrombophilia were more likely to be initiated on VKA compared with one of the NOACs. In conclusion the initiation of rivaroxaban and apixaban is increasing significantly over time in patients with VTE. Patients with previous VTE, chronic kidney disease, liver disease, cancer, and thrombophilia were more likely to be initiated on VKA compared with rivaroxaban or apixaban.
format	article
author	Caroline Sindet-Pedersen Jannik Langtved Pallisgaard Laila Staerk Jeffrey S. Berger Morten Lamberts Christian Torp-Pedersen Gunnar H. Gislason Jonas Bjerring Olesen
author_facet	Caroline Sindet-Pedersen Jannik Langtved Pallisgaard Laila Staerk Jeffrey S. Berger Morten Lamberts Christian Torp-Pedersen Gunnar H. Gislason Jonas Bjerring Olesen
author_sort	Caroline Sindet-Pedersen
title	Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
title_short	Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
title_full	Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
title_fullStr	Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
title_full_unstemmed	Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
title_sort	temporal trends in initiation of vka, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - a danish nationwide cohort study
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/a356c7fa19f545c8a9a069f90130ab95
work_keys_str_mv	AT carolinesindetpedersen temporaltrendsininitiationofvkarivaroxabanapixabananddabigatranforthetreatmentofvenousthromboembolismadanishnationwidecohortstudy AT janniklangtvedpallisgaard temporaltrendsininitiationofvkarivaroxabanapixabananddabigatranforthetreatmentofvenousthromboembolismadanishnationwidecohortstudy AT lailastaerk temporaltrendsininitiationofvkarivaroxabanapixabananddabigatranforthetreatmentofvenousthromboembolismadanishnationwidecohortstudy AT jeffreysberger temporaltrendsininitiationofvkarivaroxabanapixabananddabigatranforthetreatmentofvenousthromboembolismadanishnationwidecohortstudy AT mortenlamberts temporaltrendsininitiationofvkarivaroxabanapixabananddabigatranforthetreatmentofvenousthromboembolismadanishnationwidecohortstudy AT christiantorppedersen temporaltrendsininitiationofvkarivaroxabanapixabananddabigatranforthetreatmentofvenousthromboembolismadanishnationwidecohortstudy AT gunnarhgislason temporaltrendsininitiationofvkarivaroxabanapixabananddabigatranforthetreatmentofvenousthromboembolismadanishnationwidecohortstudy AT jonasbjerringolesen temporaltrendsininitiationofvkarivaroxabanapixabananddabigatranforthetreatmentofvenousthromboembolismadanishnationwidecohortstudy
_version_	1718388722252120064

Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study

Ejemplares similares